Loomis, Sayles & Company
SGNT

Loomis, Sayles & Company’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

Loomis, Sayles & Company’s Portfolio SGNT Stock Details SGNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-568
Closed -$9K – 1188
2015
Q4 		$9K Buy
+568
New +$8.94K ﹤0.01% 881
2014
Q1 		– Sell
-507,928
Closed -$12.9M – 800
2013
Q4 		$12.9M Buy
+507,928
New +$11.5M 0.04% 457

Other funds holding SGNT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company's SGNT Position: Q1 2016 in Review

Loomis, Sayles & Company sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q1 2016, closing a stake of 568 shares — an estimated $9K sold.

Loomis, Sayles & Company first reported a position in SGNT in Q4 2013 and held it in 2 quarters. The position peaked at $12.9M in Q4 2013. 136 funds tracked by Wall St. Rank hold SGNT as of Q1 2016.

  • Loomis, Sayles & Company reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q1 2016 after selling out during the quarter.
  • Loomis, Sayles & Company sold 568 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q1 2016, an estimated $9K.
  • Loomis, Sayles & Company first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q4 2013 and held it in 2 quarters.
  • Loomis, Sayles & Company's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $12.9M in Q4 2013.
  • 136 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q1 2016.

Based on Loomis, Sayles & Company's 13F filing for Q1 2016, filed 13 May 2016.